

3rd SURVEILLANCE CREDIT RATING REPORT FNF PHARMACEUTICALS LIMITED

Ref. no.: FR/2023/033224



Report Contents:

Particulars	Page
Rating Rationale	1
Business Profile	2
Business Management	2
Market Review	3
Business Analysis	4
Financial Position Analysis	6
Banking Relationship	7
Risk Factor Analysis	8
Rating Observation	8

SME Rating	WCRSE/WCRME	Outlook	Date of Declaration	Date of Expiration
	WCRSME3	Stable	30 August 2023	31 August 2024

Name of the Bank	Mode of Investment	Sanctioned Amount	Outstanding Amount	Tk. in million Outstanding Date
Islami Bank Bangladesh Limited	LC/Bills/MPI/TR	400.00	330.98	20.08.2023
	Commercial	1.20	1.30	
	Stimulus	50.00	54.48	

Financial Based on- Audited financial statements up to 30 June 2022.

Key Snapshot:

Particulars	Tk. in million	
	FY22	FY21
Revenue	1,109.58	694.73
EBIT	76.61	112.19
Net Profit	19.83	69.18
Total Assets	564.50	836.46
Total Equity	22.62	389.83
Debt	541.88	446.64
Net Profit Margin (%)	1.8%	10.0%
CCC (Days)	79.71	266.43
ICR (X)	1.40	3.00

Methodology: SME Rating Methodology published on the WCRCL website at www.wasocreditrating.com

RATING RATIONALE

WCRCL has reaffirmed 'WCRSME3' (pronounced as WASO Credit Rating Small and Medium Enterprise Three) rating under the SME Rating to **FNF Pharmaceuticals Limited** (hereinafter referred to as 'FNFPL' or 'The company') based on its financial and other relevant qualitative and quantitative information up-to the date of the rating assessment.


The above ratings have been assigned based on the fundamentals of the company which include experienced management, moderate regional diversification, moderate diversified product portfolio, sponsors have related experience, good interest coverage position, equipped with power backup, good infrastructural arrangement.

However, the above factors are constrained to some extent by average disclosure in the financial statement, market saturation or high competition, small portion of market share, high leverage position in the capital structure, stressed liquidity position with long cash conversion cycle, price volatility of the raw materials, no insurance coverage, minimum product range and poor area coverage.

The SME rating implies that the enterprise is adjudged to above average credit quality.

WCRCL also viewed the company with "Stable" outlook and believes that FNFPL will be able to maintain its good fundamentals in the foreseeable future. This rating may be revised in case of any extraordinary changes in line with the sponsor's equity investment, debt obligations, management, business operations and/or changes in any macro and micro factors in the economy.

**Capital Structure
(BDT. in million)**



Analysts:

Md. Rafiul bary
rafi@wasocreditrating.com

Md. Al Amin Jewel
jewel@wasocreditrating.com